ZA200408755B - Condensed purine derivatives as A1 adenosine receptor antagonists. - Google Patents

Condensed purine derivatives as A1 adenosine receptor antagonists.

Info

Publication number
ZA200408755B
ZA200408755B ZA200408755A ZA200408755A ZA200408755B ZA 200408755 B ZA200408755 B ZA 200408755B ZA 200408755 A ZA200408755 A ZA 200408755A ZA 200408755 A ZA200408755 A ZA 200408755A ZA 200408755 B ZA200408755 B ZA 200408755B
Authority
ZA
South Africa
Prior art keywords
receptor antagonists
adenosine receptor
purine derivatives
condensed purine
condensed
Prior art date
Application number
ZA200408755A
Inventor
Ko-Chung Lin
Chi Vu
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of ZA200408755B publication Critical patent/ZA200408755B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
ZA200408755A 2000-12-01 2004-10-28 Condensed purine derivatives as A1 adenosine receptor antagonists. ZA200408755B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25065800P 2000-12-01 2000-12-01

Publications (1)

Publication Number Publication Date
ZA200408755B true ZA200408755B (en) 2005-07-27

Family

ID=22948640

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200304067A ZA200304067B (en) 2000-12-01 2003-05-26 Condensed purine derivatives as A1 adenosine receptor antagonists.
ZA200408755A ZA200408755B (en) 2000-12-01 2004-10-28 Condensed purine derivatives as A1 adenosine receptor antagonists.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA200304067A ZA200304067B (en) 2000-12-01 2003-05-26 Condensed purine derivatives as A1 adenosine receptor antagonists.

Country Status (33)

Country Link
US (2) US6605601B2 (en)
EP (1) EP1347981B1 (en)
JP (2) JP2004514723A (en)
KR (1) KR20040011439A (en)
CN (1) CN100497340C (en)
AR (1) AR035400A1 (en)
AT (1) ATE394402T1 (en)
AU (2) AU2002219977B2 (en)
BG (1) BG107849A (en)
BR (1) BR0115833A (en)
CA (1) CA2430508C (en)
CZ (1) CZ20031513A3 (en)
DE (1) DE60133931D1 (en)
EA (1) EA009814B1 (en)
EE (1) EE200300260A (en)
ES (1) ES2305139T3 (en)
GE (1) GEP20094697B (en)
HK (1) HK1059927A1 (en)
HU (1) HUP0400530A3 (en)
IL (1) IL156046A0 (en)
IS (1) IS6821A (en)
MX (1) MXPA03004857A (en)
MY (1) MY127120A (en)
NO (1) NO20032483L (en)
NZ (1) NZ526511A (en)
PL (1) PL362642A1 (en)
SK (1) SK6552003A3 (en)
TR (1) TR200300766T2 (en)
TW (1) TWI293301B (en)
UA (1) UA75625C2 (en)
WO (1) WO2002044182A1 (en)
YU (1) YU42903A (en)
ZA (2) ZA200304067B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2238335T3 (en) * 1999-12-24 2005-09-01 Kyowa Hakko Kogyo Co., Ltd. CONDENSED PURINE DERIVATIVES.
GEP20094697B (en) * 2000-12-01 2009-06-10 Biogen Idec Inc Condensed purine derivatives as a1 adenosine receptor antagonists
US7202252B2 (en) * 2003-02-19 2007-04-10 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060252780A1 (en) * 2003-04-25 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. Fused pyrimidine derivatives
TW200500070A (en) 2003-04-25 2005-01-01 Novacardia Inc Method of improved diuresis in individuals with impaired renal function
WO2005009343A2 (en) * 2003-06-06 2005-02-03 Endacea, Inc. A1 adenosine receptor antogonists
MX2007010984A (en) * 2005-03-11 2008-03-18 Aderis Pharmaceuticals Inc Substituted 9-alkyladenines and the use thereof.
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
AU2007235372A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine A1 receptor antagonists and anticonvulsants
DK2018380T3 (en) 2006-05-19 2012-01-23 Abbott Lab CNS-activated condensed bi-heterocyclic-substituted azabicyclic alkane derivatives
JP2009540003A (en) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Long-term improvement in renal function including low frequency administration of AA1RA
ATE486874T1 (en) 2006-06-23 2010-11-15 Incyte Corp PURINONE DERIVATIVES AS HM74A AGONISTS
BRPI0713619A2 (en) 2006-06-23 2013-01-15 Incyte Corp compound or prodrug or pharmaceutically acceptable salt thereof, composition, and use of the compound.
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2011063268A2 (en) * 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
KR20200106176A (en) 2018-01-04 2020-09-11 임페티스 바이오사이언시즈 엘티디. Tricyclic compounds, compositions containing tricyclic compounds, and pharmaceutical uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102662B2 (en) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 Xanthine derivative
ES2152207T3 (en) * 1989-10-20 2001-02-01 Kyowa Hakko Kogyo Kk CONDENSED DERIVATIVES OF LA PURINA.
EP0884314B1 (en) 1991-09-23 2004-01-21 Florida State University Metal alkoxides
EP0884318A4 (en) * 1996-10-07 2002-10-23 Kyowa Hakko Kogyo Kk Fused purine derivatives
WO1998057651A1 (en) * 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
CA2336412C (en) * 1998-07-02 2007-11-27 Junichi Shimada Medicament for treatment of diabetes
ES2238335T3 (en) * 1999-12-24 2005-09-01 Kyowa Hakko Kogyo Co., Ltd. CONDENSED PURINE DERIVATIVES.
GEP20094697B (en) * 2000-12-01 2009-06-10 Biogen Idec Inc Condensed purine derivatives as a1 adenosine receptor antagonists

Also Published As

Publication number Publication date
US6605601B2 (en) 2003-08-12
IS6821A (en) 2003-05-20
YU42903A (en) 2006-05-25
EA200300629A1 (en) 2003-12-25
GEP20094697B (en) 2009-06-10
JP2004514723A (en) 2004-05-20
ATE394402T1 (en) 2008-05-15
NO20032483L (en) 2003-07-30
HUP0400530A3 (en) 2007-05-29
CZ20031513A3 (en) 2003-09-17
MXPA03004857A (en) 2003-08-19
EE200300260A (en) 2003-08-15
HK1059927A1 (en) 2004-07-23
KR20040011439A (en) 2004-02-05
UA75625C2 (en) 2006-05-15
ZA200304067B (en) 2005-05-30
BG107849A (en) 2004-01-30
SK6552003A3 (en) 2003-12-02
TWI293301B (en) 2008-02-11
US20020111333A1 (en) 2002-08-15
EP1347981A1 (en) 2003-10-01
AU2002219977B2 (en) 2008-01-24
DE60133931D1 (en) 2008-06-19
JP2010053148A (en) 2010-03-11
EA009814B1 (en) 2008-04-28
WO2002044182A1 (en) 2002-06-06
NO20032483D0 (en) 2003-06-02
ES2305139T3 (en) 2008-11-01
EP1347981B1 (en) 2008-05-07
PL362642A1 (en) 2004-11-02
HUP0400530A2 (en) 2004-06-28
IL156046A0 (en) 2003-12-23
NZ526511A (en) 2005-04-29
CN100497340C (en) 2009-06-10
US7022686B2 (en) 2006-04-04
BR0115833A (en) 2003-10-28
US20030220358A1 (en) 2003-11-27
AR035400A1 (en) 2004-05-26
CN1481387A (en) 2004-03-10
CA2430508C (en) 2010-05-18
AU1997702A (en) 2002-06-11
CA2430508A1 (en) 2002-06-06
TR200300766T2 (en) 2004-09-21
MY127120A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
AU6808901A (en) Adenosine a2a receptor antagonists
ZA200408755B (en) Condensed purine derivatives as A1 adenosine receptor antagonists.
HUP0401925A3 (en) A2b adenosine receptor antagonists
IL161716A0 (en) ADENOSINE A2a RECEPTOR ANTAGONISTS
IL161572A0 (en) Adenosine a2a receptor antagonists
MXPA03001143A (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists.
MXPA03001775A (en) Nucleoside derivatives.
MXPA03002269A (en) Purine derivatives.
MXPA03008967A (en) 8-heteroaryl xanthine adenosine a2b receptor antagonists.
HUP0401437A3 (en) Adenosine a3 receptor agonists
MXPA03000078A (en) Purine derivatives.
AU5640299A (en) 4-quinolinemethanol derivatives as purine receptor antagonists.(ii)
HK1047942A1 (en) Purine derivatives.
HK1047111A1 (en) Purine derivatives.
HK1047110A1 (en) Purine derivatives.
HK1064097A1 (en) Bicyclic Ä1,2,4Ü -triazole adenosine a2a receptor antagonists
HK1058360A1 (en) 4-Phenyl-pyridine derivatives as neurokinin-1 receptor antagonists.
NO20020931D0 (en) Pyrrolo [2,3-d] pyrimidine nucleoside analogs
HK1049835A1 (en) Selective antagonists of a2b adenosine receptors a2b.
HUP0303533A3 (en) Adenosine a1 agonist adenosine derivatives
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
AU3167402A (en) Aminotriazolopyridiine derivatives as adenosine receptor ligands
EP1636230A4 (en) A1 adenosine receptor antagonists
SI1401837T1 (en) Purine derivatives as a2b adenosine receptor antagonists
HUP0203369A3 (en) Polycycloalkylpurines as adenosine receptor antagonists, process for their preparation and their use